SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer’s disease in the world.
The transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream. It will enable the number of doses to be reduced, make it easier to be used for patients with Alzheimer’s disease who have difficulty in swallowing, and also reduce the burden of caregivers or family members when administering it to patients.
About Teikoku
Teikoku Pharma USA Inc. is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; chronic and acute Pain and CNS. Teikoku’s main product is Lidoderm(R) (lidocaine 5% patch) for PHN (post herpetic neuralgia) , in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmBH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.
Teikoku’s commitment is to expand Trandermal technologies for the benefit of patients and partners. For more information, please visit www.teikokuusa.com
About Eisai
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, integrative oncology, and vascular/immunology reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. For more information, please visit www.eisai.co.jp .
CONTACT: Francisco Bejar, Associate Director Business Development of
Teikoku Pharma USA Inc., +1-408-501-1804, fbejar@teikokuusa.com
Web site: http://teikokuusa.com/
